Search

Displaying results 2531 - 2540 of 3732 in total
  1. Drug

    Avenciguat

    go.drugbank.com/drugs/DB18882
    Investigational

    Avenciguat is under investigation in clinical trial NCT05282121 (A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (N...

    Categories: P-glycoprotein substrates
  2. Drug

    Epaminurad

    go.drugbank.com/drugs/DB18973
    Investigational

    Epaminurad is under investigation in clinical trial NCT05815901 (A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  3. Drug

    Bersacapavir

    go.drugbank.com/drugs/DB19035
    Investigational

    Bersacapavir is under investigation in clinical trial NCT03365947 (Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)).

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 Substrates
  4. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    Imlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader. … The FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with

    Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor Degraders
  5. Drug

    p-Boronophenylalanine

    go.drugbank.com/drugs/DB19158
    Investigational

    p-Boronophenylalanine is under investigation in clinical trial NCT00039572 (Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain).

    Synonyms: L-p-boronophenylalanine
  6. Drug

    Human placenta hydrolysate

    go.drugbank.com/drugs/DB19297
    Investigational

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  7. Drug

    Benzgalantamine

    go.drugbank.com/drugs/DB19353
    ApprovedInvestigational

    Benzgalantamine is a prodrug of galantamine. Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason fo...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  8. Drug

    Hydrastine

    go.drugbank.com/drugs/DB19354
    Experimental

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with rituximab (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse o...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  10. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. It inhibits TYK2- and JAK1-mediated cytokine signaling, blocking phosphorylation of signal transducers and activat...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors